Effect of Memantine on Radiotherapy-related Cognitive Impairment
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Purpose: This randomized, double-blind, placebo-controlled clinical trial aims to evaluate
the therapeutic effects of thalidomide in radiotherapy-related cognitive impairment.
Further study details as provided by Sun Yat-sen Memorial Hospital, Sun Yat-sen University /
Yameitang.
Primary outcome measure: cognitive improvement, which is determined by the difference value
of ADAS-cog score before and after the treatment of memantine.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University